Bachelor's DegreesBachelor of ArtsBachelor of EngineeringDual-Degree Program
Master's DegreesMaster of ScienceMaster of EngineeringMaster of Engineering Management
Doctoral DegreesDoctor of PhilosophyPhD Innovation ProgramPhD + Doctor of Medicine
Startups listed byStartup Names Faculty Founders Research Programs
Patents listed byPatent Titles Faculty Inventors Research Programs
All Thayer News
Adagio Files for IPO, Sees Need for COVID Treatments for ‘Years to Come’
Jul 19, 2021 | The Boston Globe
The Boston Globe reports on Adagio Therapeutics, a startup co-founded by Dartmouth Engineering Professor Tillman Gerngross to fight coronaviruses.
"Adagio Therapeutics, a Waltham biotech, disclosed in a public filing Friday that it is planning to go public one year after it was founded to advance COVID-19 antibody therapies.
"The company, which spun out of New Hampshire-based Adimab, is developing drugs that aim to treat and prevent illness caused by the coronavirus, and by new variants.
"Although three COVID-19 vaccines have been authorized for emergency use by the Food and Drug Administration, it is Adagio's idea that the current pandemic will continue to require a 'variety of effective, safe and convenient treatment and prevention options for years to come,' according to a filing with the Securities and Exchange Commission."
..."Adimab, which licensed anticoronavirus antibodies to Adagio, is the largest stockholder in the firm, with a roughly 31 percent stake. Dartmouth professor and serial entrepreneur Tillman Gerngross is the cofounder and chief executive of both firms. Investors with more than a 5 percent stake in the company include Fidelity Management & Research Co., GV, Mithril, OrbiMed, Polaris Partners, and RA Capital."
Similar coverage in: MSN
Link to source:
For contacts and other media information visit our Media Resources page.